公开(公告)号：EP1294893B1

公开(公告)日：2006-03-15

申请号：EP01943625.2

申请日：2001-06-22

申请人： UCB Pharma Limited

发明人： PAGE, Mark ,  LI, Jing-Li ,  PUMPENS, Paul Biomedical Research and Study Centre ,  BORISOVA, Galina, Biomedical Research& Study Ctr.

IPC分类号： C12N15/51 ,  C07K14/02 ,  A61K39/29 ,  A61P31/20

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/525 ,  C12N2730/10122 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/484

摘要： A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.

公开(公告)号：EP0725653B2

公开(公告)日：2008-04-02

申请号：EP94928455.8

申请日：1994-10-04

申请人： UCB Pharma Limited

发明人： ROBERTS, Mark, Medeva Vaccine Res. Unit, Imperial

IPC分类号： A61K39/10

CPC分类号： C07K14/235 ,  A61K39/00

摘要： The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against B. pertussis infection. The invention also relates to the use of a non-toxic double mutant form of pertussis toxin for the manufacture of an adjuvant composition for stimulating or enhancing a protective immune response of an antigen co-administered therewith. The non-toxic double mutant is preferably one in which the glutamic acid 129 amino acid in the S1 sub-unit has been substituted by glycine and the arginine 9 amino acid has been substituted by lysine.